About Tumor necrosis factor receptor superfamily member 3
Tumor necrosis factor receptor superfamily member 3 (LTBR) is a protein
from Homo sapiens identified by UniProt accession
P36941, 435 residues long.
MolForge cross-references it against 0 known binders and
388 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 3 |
| UniProt accession | P36941 |
| Gene | LTBR |
| Organism | Homo sapiens |
| Length | 435 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (388)
Diseases linked to this target (Open Targets).
- monocyte count · score 0.27
- lymphocyte count · score 0.27
- platelet count · score 0.26
- leukocyte count · score 0.25
- platelet crit · score 0.24
- eosinophil count · score 0.24
- monocyte percentage of leukocytes · score 0.23
- lymphocyte percentage of leukocytes · score 0.23
- reticulocyte count · score 0.23
- aspartate aminotransferase measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P36941-F1 | alphafold | PREDICTED | 66.58 | — |
Amino-acid sequence (435 residues)
MLLPWATSAP GLAWGPLVLG LFGLLAASQP QAVPPYASEN QTCRDQEKEY YEPQHRICCS RCPPGTYVSA KCSRIRDTVC ATCAENSYNE HWNYLTICQL CRPCDPVMGL EEIAPCTSKR KTQCRCQPGM FCAAWALECT HCELLSDCPP GTEAELKDEV GKGNNHCVPC KAGHFQNTSS PSARCQPHTR CENQGLVEAA PGTAQSDTTC KNPLEPLPPE MSGTMLMLAV LLPLAFFLLL ATVFSCIWKS HPSLCRKLGS LLKRRPQGEG PNPVAGSWEP PKAHPYFPDL VQPLLPISGD VSPVSTGLPA APVLEAGVPQ QQSPLDLTRE PQLEPGEQSQ VAHGTNGIHV TGGSMTITGN IYIYNGPVLG GPPGPGDLPA TPEPPYPIPE EGDPGPPGLS TPHQEDGKAW HLAETEHCGA TPSNRGPRNQ FITHD
Explore Tumor necrosis factor receptor superfamily member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets